Total amount: € 0,00
Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,6
Online ISSN 1827-1898
Peizeng HU 1, 2, Yongchen MA 1, 2, Lingling ZHANG 3, Sheng MA 1
1 Yidu Central Hosptial of Weifang, Weifang, Shandong, China; 2 School of Medicine, Shandong University, Jinan, Shandong, China; 3 Shandong Province Rongjun Hospital, Weifang, Shandong, China
BACKGROUND: The results involved in correlation of PON1 L55M polymorphism and cancer risk are still inconsistent and controversial. Therefore, we performed this comprehensive meta-analysis for the effects of PON1 L55M polymorphism and cancer risk.
METHODS: We carried out a PubMed (Medline), EMBASE database search covering all published articles. The strength of association between PON1 L55M polymorphism and cancer risk was estimated by pooled ORs with corresponding 95% CIs.
RESULTS: Twenty one independent case-control studies concerned with association between PON1 L55M polymorphism and cancer risk were finally included in this meta-analysis. We found that there was a statistical significance between PON1 L55M polymorphism and cancer risk (OR=1.21, 95% CI=1.04-1.40). In stratified analyses by site of cancer, statistically significant increased breast cancer risk was found (OR=2.04, 95% CI=1.29-3.21). In stratified analyses by ethnicity, statistically significant increased cancer risk was found in Caucasian populations (OR=1.25, 95% CI=1.03-1.51). In stratified analyses by source of control, significant increased cancer risk was found in hospital-based studies (OR=1.26, 95% CI=1.10-1.44).
CONCLUSIONS: This meta-analysis suggested that PON1 L55M polymorphism might increase the risk of cancer.